Oligonucleotide therapeutics — Novel cardiovascular targets

[1]  M. Aoki,et al.  Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide , 1997, Nature Medicine.

[2]  T. Ogihara,et al.  In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction , 1997, Nature Medicine.

[3]  David Baltimore,et al.  An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death , 1996, Science.

[4]  C. Stein,et al.  Does antisense exist? , 1995, Nature Medicine.

[5]  C. Stein,et al.  Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix (*) , 1995, The Journal of Biological Chemistry.

[6]  G. R. Dodge,et al.  Transcatheter Delivery of c‐myc Antisense Oligomers Reduces Neointimal Formation in a Porcine Model of Coronary Artery Balloon Injury , 1994, Circulation.

[7]  Fibrinolytictherapytrialistsf.  Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[8]  T. Ogihara,et al.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Michael Simons,et al.  Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo , 1992, Nature.

[10]  M E Billingham,et al.  Cardiac transplant atherosclerosis. , 1987, Transplantation proceedings.

[11]  H. Granger,et al.  Molecular and cellular basis of myocardial angiogenesis. , 1994, Cellular & molecular biology research.

[12]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .